The trial met the primary and secondary endpoints of safety, tolerability and pharmacokinetics.
The antibody received FDA orphan drug designation to treat systemic capillary leak syndrome earlier this year.
Under the partnership, Walgreens will provide patient recruitment services to support the ongoing trial.
The detection of minimal residual disease by second-look laparoscopy is the primary endpoint of the study.
An improved ACR20 response was observed in 54.7% of patients treated with resomelagon, against 55.7% of patients receiving a placebo.
Give your business an edge with our leading industry insights.
NPX267 targets killer cell immunoglobulin-like receptor 3DL3 and helps prevent immune escape in solid tumours.
Eligible participants for the trial need to attend up to 12 visits at the Sunshine Coast clinic for around 15 months.
Lindus Health plans to launch clinical trials for menopause, insomnia, tinnitus, and childhood myopia treatments.
SignalPath will configure study protocol workflows within the platform and save time and effort of the site staff.
Bitopertin was well-tolerated at both dose levels and no serious adverse events were reported.